NEWARK, Del, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The global atopic dermatitis treatment market size is estimated to reach a valuation of USD 15,048.6 million in 2024. The industry is projected to be worth USD 43,241.1 million by 2034, expanding at a CAGR of 11.1% between 2024 and 2034. The rising prevalence of atopic dermatitis emerges as a prominent driver for the market, impacting a substantial portion of the global population and amplifying the demand for effective treatment solutions.
The growth trajectory faces counterbalances from ongoing advancements in therapeutic technologies, particularly the development of targeted biologics and topical formulations. These innovations, characterized by enhanced efficacy and safety profiles, contribute to improved patient outcomes, shaping the landscape of atopic dermatitis treatment.
Despite challenges, significant opportunities exist within the market, notably propelled by the expanding healthcare infrastructure in emerging markets. As economic growth and healthcare investments rise in these regions, the demand for effective atopic dermatitis treatments is expected to surge, creating a conducive market environment.
Get Recently Updated Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-3097
A notable limitation looms over the market in the form of high treatment costs. The economic burden associated with long-term care, encompassing medication expenses and wellness visits, poses challenges for patients, constraining their access to suitable treatment options.
The dichotomy between the growing demand for advanced treatments driven by atopic dermatitis prevalence and the financial constraints imposed by treatment costs defines the dynamics of the atopic dermatitis treatment market.
Overcoming these challenges demands strategic approaches that balance innovation, accessibility, and affordability. As the industry navigates these complexities, the relentless pursuit of improved treatments and a nuanced understanding of economic disparities will play a pivotal role in shaping the future landscape of atopic dermatitis therapeutics.
Atopic dermatitis is the most common form of eczema, a skin disorder that causes itchy, dry, and cracked skin. The rise in prevalence of the same has become a worldwide burden for the population. It is at high risk with the patient suffering from asthma and allergic rhinitis as part of an allergic triad that can lead to morbidity.
As a result, the rising prevalence of dermatological skin disorders developed in early childhood and more commonly found as a genetic disorder is driving up the need for an effective atopic dermatitis treatment market. This burdensome disease has increased the focus of manufacturers to develop an effective treatment line for atopic dermatitis in high demand which in turn has enhanced the atopic dermatitis treatment market.
As there is no such treatment that can cure atopic dermatitis disorder completely, many alternative treatment lines are available and more are on the horizon. There are currently an unprecedented number of new treatments for eczema in development that has opened up new therapy possibilities with little morbidity. This includes treatments using drugs like corticosteroids, antibiotics, emollients, biological therapies, etc.
Key Takeaways from the Market Study:
- Based on product type, biologic therapy is expected to hold a market share of 26.3% in 2024.
- The United States is estimated to register at a CAGR of 13.7% by 2034.
- Germany experiences significant growth, projected at a CAGR of 12.8% by 2034.
- Based on end-user type, hospital pharmacies are anticipated to hold a market share of 29.5% in 2024.
“The increasing occurrence of atopic dermatitis acts as a key driving force in the market, impacting a significant portion of the global population,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).
Which Factors Are Restraining the Demand for Atopic Dermatitis Treatment?
Currently, many developing and underdeveloped nations lack skin treatment owing to its side effects, high treatment cost, and absence of reimbursement policies in developing countries.
The treatment cost of atopic dermatitis is the main factor restraining the market growth. Based on available evidence, annual pediatric atopic dermatitis costs are generally high. Variations in cost estimates are due to study differences in the country of analysis, types of costs included, the severity of atopic dermatitis, and costing methodology.
But generally, the burden of the treatment for atopic dermatitis is borne by the patient mainly in the Asia Pacific and African countries due to the absence of any reimbursement policies in this region.
Additionally, many times, due to severe atopic conditions, the medications and treatment for atopic dermatitis can be very expensive. For example, Crisaborole costs almost US$ 1,500/patient while the developers of the biologic therapy Dupixent have priced the drug at approximately US$ 37,000/year.
It is uncertain if payers will cover the cost of treatment, considering other lower-cost alternatives. This could hinder the adoption of the drug. However, the scenario is the contrast in a few of the developing and underdeveloped economies.
Additionally, corticosteroids have many side effects, dermatologists don’t usually recommend steroids for the treatment of atopic dermatitis. Although oral corticosteroids are approved for the treatment of Atopic Dermatitis, dermatologists do not recommend their use because of rebound on discontinuation.
Dupixent can cause side effects such as serious allergic reactions and eye problems, such as pink eye (conjunctivitis) and inflammation of the cornea (keratitis). On the other hand, the most common side effects include cold sores in the mouth or on the lips; injection site reactions; and eye and eyelid inflammation, including swelling, redness, and itching.
Thus all these factors can prove to be a major restraining factor for the drug class segment of the atopic dermatitis treatment market.
Competitive Landscape:
The competitive landscape of the atopic dermatitis treatment market is characterized by robust innovation and strategic advancements in therapeutic technologies.
Key players in the market continually strive to develop targeted biologics and topical formulations, enhancing treatment efficacy and safety. The evolving healthcare infrastructure in emerging markets presents lucrative opportunities for market expansion.
Despite challenges related to treatment costs, the market remains dynamic, driven by a commitment to addressing the growing demand for effective atopic dermatitis treatments globally.
Some of the recent developments are:
- In June 2022, Sanofi reported the approval of Dupixent by the US Food and Drug Administration for children aged 6 months to 5 years dealing with atopic dermatitis.
This signifies a significant advancement in treatment options for this age group.
- In January 2022, AbbVie Inc. announced the United States FDA approval of RINVOQ for treating severe atopic dermatitis in individuals aged 12 and older. RINVOQ is prescribed for patients who have not responded to previous injection or tablet treatments, offering a new therapeutic avenue for those with challenging conditions.
Discover Key Insights Request Full Report Access Now! https://www.futuremarketinsights.com/checkout/3097
Key Companies Profiled:
- Sanofi SA
- Galderma SA
- Allergan Plc.
- Novartis
- Bristol-Myers Squibb
- Bayer AG
- Meda Pharmaceuticals
- Astellas Pharma Inc.
- Anacor Pharmaceutical Inc.
- Regeneron Pharmaceuticals
Key Segments of Atopic Dermatitis Treatment Industry Survey:
By Product:
- Corticosteroids
- Calcineurin Inhibitors
- Immunosuppressants
- Biologic Therapy
- PDE-4 Inhibitor
- Antibiotics
- Antihistamines
- Emollients
By Indication:
- Topical
- Oral
- Injectable
By End User:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Dermatology Clinics
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- Middle East and Africa
Authored By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain:
The global canine atopic dermatitis treatment market size expects a considerable valuation bump, from USD 1,182.60 million in 2024 to USD 1,620.50 million in 2034. The updated report points to a CAGR of 3.20% CAGR from 2024 to 2034.
The global feline atopic dermatitis treatment market sales is slated to expand at a positive 4.5% CAGR and is likely to reach USD 7 billion by 2032. Sales in the feline atopic dermatitis treatment market are expected to reach USD 5 Billion in 2022.
The global biomedical refrigerator and freezer market share is anticipated to be worth USD 6,053.8 million by 2034. According to the estimates, the market is projected to clock a 5.60% CAGR until 2034. In 2024, the biomedical refrigerator and freezer market size is valued at USD 3,510.65 million.
The global cryopreservation freezers market demand is expected to grow at a CAGR of 6.5%. The market value is projected to increase from USD 585.0 Million in 2023 to USD 1.1 Billion by 2033.
The global venous stents market strategies valued at approximately USD 990.5 million in 2023, is expected to soar to an impressive USD 2.2 billion by the end of 2033. This growth represents a substantial compound annual growth rate (CAGR) of 8.4% from 2023 to 2033.
The global intravenous pegloticase market trends with a slowly progressing CAGR of 13.8% from 2023 to 2033, this market is expected to garner USD 3.19 Billion by 2023 and USD 11.61 Billion by 2033.
The projected global photoacoustic microscopy market opportunity is likely to hit the USD 120 billion valuation mark by 2024. Owing to an impressive CAGR of 17.3% through 2034, the ecosystem is set to reach USD 591.6 million by the end of the forecast period.
The global intravenous iron drugs market forecast is projected to reach USD 2.8 Billion in 2022 and is expected to growth USD 6.3 Billion by 2032 at a CAGR of 8.5%.
The global bone cement delivery system market outlook is expected to expand at a CAGR of 6.2% through 2034. The industry value is projected to increase from USD 942.4 million in 2024 to USD 1,719.8 million by 2034.
The global elastography imaging market overview is expected to progress at a CAGR of 10.5%. The industry’s value is projected to increase from USD 3,841.6 million in 2024 to USD 10,426.4 million by 2034.
The global intracardiac imaging market growth is expected to advance at a CAGR of 5.8%. The value of the industry is projected to increase from USD 744.3 million in 2024 to USD 1,308 million by 2034.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
